Here’s an
interesting article from a new source of CPD I’ve started following.
TheScientistDaily I can distinctly remember talk of Herceptin a year or so ago.
I *think I blogged about it here but (I won’t lie) I can’t be bothered
to dig through the archives to find what I said.
But this
article has researchers questioning whether Herceptin is as good as it was
billed, and if current clinical guidelines for classifying and treating breast
cancer may be off the mark. New classification schemes may better identify
those patients more likely to benefit from anti-HER2 treatment or point to
therapies that might be more effective.
Perhaps
not directly relevant to what I do, but it makes me wonder just how wonderful
the latest “wonder treatments” actually are. And how long it will be
before the new classification schemes are superseded?
I can
remember reading that NASA refused to allow technology less than five years
onto their space probes as they wanted tried-and-tested technology; it’s no
good finding problems when the space probe is half the solar system away.
No comments:
Post a Comment